https://galvanizetx.com/news-post/gala-therapeutics-receives-fda-ide-approval-for-a-us-early-feasibility-study-of-its-rheox-system-to-treat-chronic-bronchitis/2022-12-16T23:10:23+00:00https://galvanizetx.com/news-post/data-from-first-in-human-rheox-bronchial-rheoplasty-trial-to-be-presented-at-the-european-respiratory-society/2022-12-16T23:10:41+00:00https://galvanizetx.com/news-post/gala-presents-positive-results-from-first-in-human-clinical-trial-of-rheox-in-chronic-bronchitis-at-the-european-respiratory-society/2022-12-16T23:10:56+00:00https://galvanizetx.com/news-post/gala-enrolls-first-subjects-in-an-early-feasibility-study-of-rheox-for-chronic-bronchitis-in-the-united-states/2022-12-16T23:11:17+00:00https://galvanizetx.com/news-post/gala-enrolls-first-subject-at-temple-lung-center-as-part-of-the-us-early-feasibility-trial-of-rheox-for-chronic-bronchitis-in-the-united-states/2022-12-16T23:11:44+00:00https://galvanizetx.com/news-post/new-data-from-first-in-human-study-of-rheox-device-based-therapy-for-chronic-bronchitis-to-be-presented-at-ats-2019/2022-12-16T23:12:02+00:00https://galvanizetx.com/news-post/initial-study-of-the-minimally-invasive-rheox-device-demonstrates-positive-results-for-chronic-bronchitis-patients/2022-12-16T23:12:17+00:00https://galvanizetx.com/news-post/gala-therapeutics-receives-ce-mark-for-its-minimally-invasive-rheox-system-for-chronic-bronchitis/2022-12-16T23:12:49+00:00https://galvanizetx.com/news-post/gala-therapeutics-receives-fda-breakthrough-device-designation-for-the-minimally-invasive-rheox-system-for-chronic-bronchitis/2022-12-16T23:13:09+00:00https://galvanizetx.com/news-post/new-clinical-results-from-rheox-system-for-chronic-bronchitis-to-be-presented-at-european-respiratory-society-ers-international-congress/2022-12-16T23:13:25+00:00https://galvanizetx.com/news-post/gala-therapeutics-announces-publication-of-multicenter-study-of-the-minimally-invasive-rheox-system-in-patients-with-chronic-bronchitis/2022-12-16T23:13:42+00:00https://galvanizetx.com/news-post/gala-therapeutics-rheox-system-showcased-in-live-case-at-virtual-european-respiratory-society-ers-congress-as-part-of-post-market-chronic-bronchitis-study/2022-12-16T23:13:55+00:00https://galvanizetx.com/news-post/first-patients-treated-with-galaxy-medicals-centauri-pulsed-electric-field-cardiac-ablation-system/2022-12-16T23:14:11+00:00https://galvanizetx.com/news-post/galaxy-medical-centauri-pef-generator-to-be-used-during-recorded-case-presentation-at-af-symposium/2022-12-16T23:14:25+00:00https://galvanizetx.com/news-post/gala-therapeutics-receives-fda-approval-to-commence-pivotal-trial-to-evaluate-the-rheox-system-for-chronic-bronchitis/2022-12-16T23:14:42+00:00https://galvanizetx.com/news-post/doug-godshall-to-chair-gala-therapeutics-board-of-directors/2022-12-16T23:15:23+00:00https://galvanizetx.com/news-post/galaxy-medical-receives-18-million-from-atp-to-advance-development-of-its-novel-pulsed-electric-field-ablation-therapy-for-cardiac-arrhythmias/2022-12-16T23:15:39+00:00https://galvanizetx.com/news-post/galaxy-medical-eclipse-af-study-to-be-featured-in-innovative-technology-session-at-ehra-2021-annual-scientific-meeting/2022-12-16T23:15:55+00:00https://galvanizetx.com/news-post/galaxy-medical-and-japan-lifeline-enter-distribution-agreement-for-novel-pulsed-electric-field-focal-ablation-catheter/2022-12-16T23:16:12+00:00https://galvanizetx.com/news-post/gala-therapeutics-announces-first-patients-enrolled-in-pivotal-trial-of-rheox-system-for-chronic-bronchitis/2022-12-16T23:16:25+00:00https://galvanizetx.com/news-post/galaxy-medicals-eclipse-af-study-90-day-remapping-results-to-be-featured-at-the-2021-stanford-biodesign-new-arrhythmia-technologies-retreat/2022-12-16T23:16:40+00:00https://galvanizetx.com/news-post/galaxy-medical-releases-eclipse-af-remapping-data-at-stanford-biodesign-retreat-and-update-on-system-interoperability/2022-12-16T23:16:54+00:00https://galvanizetx.com/news-post/galaxy-medical-enrolls-first-patients-in-space-af-study/2022-12-16T23:17:09+00:00https://galvanizetx.com/news-post/data-from-multiple-studies-show-positive-outcomes-with-gala-therapeutics-rheox-system-for-chronic-bronchitis/2022-12-16T23:17:25+00:00https://galvanizetx.com/news-post/galaxy-medical-receives-ce-mark-for-centauri-pulsed-electric-field-system/2022-12-16T23:17:42+00:00https://galvanizetx.com/news-post/gala-therapeutics-announces-first-commercial-cases-worldwide-with-rheox-system-for-chronic-bronchitis/2022-12-16T23:18:01+00:00https://galvanizetx.com/news-post/galvanize-therapeutics-announces-merger-to-create-the-premier-pulsed-electric-field-therapy-company-and-completion-of-100-million-series-b-financing/2022-12-16T23:18:16+00:00https://galvanizetx.com/news-post/galvanize-therapeutics-presents-clinical-data-using-pulsed-electric-field-pef-energy-for-non-small-cell-lung-cancer/2022-12-16T23:19:57+00:00https://galvanizetx.com/news-post/new-interventional-oncology-data-show-potential-for-aliya-pulsed-electric-field-pef-system-in-treatment-of-solid-tumors/2023-06-07T18:51:41+00:00https://galvanizetx.com/news-post/galvanize-announces-license-agreement-and-partnership-with-energenx-medical-for-its-technologies-in-china/2023-06-07T18:52:34+00:00https://galvanizetx.com/news-post/galvanize-presents-preclinical-data-on-aliya-pef-in-combination-with-anti-pd1-in-a-murine-triple-negative-breast-cancer-model-at-the-2023-american-society-of-clinical-oncology-meeting/2023-06-08T21:05:45+00:00https://galvanizetx.com/news-post/galvanize-therapeutics-completes-enrollment-in-pivotal-trial-of-rheox-system-for-chronic-bronchitis/2023-06-19T14:45:19+00:00https://galvanizetx.com/news-post/galvanize-therapeutics-begins-u-s-clinical-study-using-aliya-pulsed-electric-field-pef-for-stage-iv-non-small-cell-lung-cancer-or-metastasis-to-the-lung/2023-09-20T14:01:45+00:00https://galvanizetx.com/news-post/galvanize-therapeutics-announces-promising-data-on-the-aliya-pulsed-electric-field-pef-system-in-early-stage-non-small-cell-lung-cancer/2023-11-06T14:46:06+00:00https://galvanizetx.com/news-post/galvanize-receives-fda-clearance-for-the-inumi-flex-endoscopic-needle-expanding-its-aliya-pulsed-electric-field-pef-portfolio-for-soft-tissue-ablation/2024-05-28T13:40:26+00:00https://galvanizetx.com/news-post/galvanize-appoints-executive-chairman-and-new-oncology-focused-director-to-the-board-of-directors/2024-07-02T13:34:39+00:00https://galvanizetx.com/news-post/galvanize-therapeutics-completes-enrollment-in-clinical-trial-evaluating-aliya-pulsed-electric-field-pef-system-for-late-stage-non-small-cell-lung-cancer-and-metastasis-to-the-lung/2024-08-06T13:48:57+00:00https://galvanizetx.com/news-post/new-study-published-on-the-safety-and-feasibility-of-pulsed-electric-field-ablation-for-early-stage-non-small-cell-lung-cancer-prior-to-surgical-resection/2025-05-20T16:24:40+00:00https://galvanizetx.com/news-post/galvanize-announces-first-patient-enrolled-in-the-propel-registry-evaluating-aliya-pulsed-electric-field-ablation-for-soft-tissue-lesions/2025-08-15T22:21:07+00:00https://galvanizetx.com/news-post/galvanize-therapeutics-raises-100-million-in-oversubscribed-series-c-financing-to-transform-the-treatment-of-cancer-and-chronic-lung-disease/2025-09-03T14:08:19+00:00https://galvanizetx.com/news-post/new-study-shows-aliya-pulsed-electric-field-ablation-achieved-local-control-of-lung-tumors-in-metastatic-cancer-patients-and-may-induce-an-immune-response/2025-12-18T21:11:56+00:00https://galvanizetx.com/news-post/galvanize-therapeutics-appoints-laura-francis-to-its-board-of-directors/2025-12-18T21:15:49+00:00